The receipt of a notice of allowance for an additional US patent is a positive development for ReShape Lifesciences, as it not only enhances its intellectual property portfolio but also potentially improves its competitive edge in the market for obesity management solutions. This could lead to increased investor confidence and a positive impact on the company's stock price in the short term.